my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
28-03-2012: Genmab A/S announced that GlaxoSmithKline (GSK) has agreed a settlement with Genentech Inc. and City of Hope (a California not-for-profit organization) concerning two U.S. patents that relate to recombinant antibody production for ofatumumab. GSK is Genmab’s development and commercial collaborator for the CD20 antibody ofatumumab. The dispute concerned U.S. Patents No 6,331,415 and U.S. No 7,923,221 (the Cabilly II and Cabilly III patents) issued to Genentech, Inc. and City of Hope. No further terms of the settlement are disclosed.
The case was initiated by GSK in October 2009 and has been pending before the United States District Court for the Central District of California. The settlement means that the pending court case will now be concluded. The two patents are due to expire in December 2018.
The settlement is not expected to affect Genmab's financial guidance for 2012.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Genmab announces patent settlement agreement for ofatumumab
Genmab A/S announced that GlaxoSmithKline (GSK) has agreed a settlement with Genentech Inc. and City of Hope (a California not-for-profit organization) concerning two U.S. patents that relate to recombinant antibody production for ofatumumab. GSK is Genmab’s development and commercial colla ... more
Genmab Reaches Second Milestone in Lundbeck Collaboration
Genmab A/S announced it had reached the second pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment. Genmab has reached the second milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders ... more
Genmab announces progress with Lundbeck collaboration
Genmab A/S announced it had reached the first pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment. Genmab has reached the first milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders o ... more
Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of p ... more
Priaxon enters collaboration with GSK on Protein-Protein-Interactions
Priaxon announced a collaboration with GlaxoSmithKline (GSK) to research and develop small molecule modulators of protein-protein-interactions. Priaxon will provide its innovative and proprietary small molecule drug discovery expertise which is particularly suited to investigating the modul ... more
Prosensa has selected clinical candidates for two more compounds for the treatment of Duchenne muscular dystrophy (DMD) and has been granted orphan drug designation for two additional DMD compounds in its pipeline.Prosensa identified suitable oligonucleotide candidates for PRO052 and PRO055 ... more
KineMed Announces Biomarker Discovery Collaboration with GSK
KineMed, Inc. announced a multi-year R&D collaboration with GlaxoSmithKline plc (GSK) that will apply KineMed’s proprietary biomarker discovery platform in therapeutic areas of interest to GSK. The collaboration will seek to identify, optimize and validate novel biomarkers that would enable ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
